News - HotSpot Therapeutics
Press Releases
Media Contact
Natalie Wildenradt
HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026
BOSTON, Mass., June 4, 2026 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric...
Read more
HotSpot Therapeutics to Present Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026
BOSTON, Mass., May 20, 2026 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric...
Read more
HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at 15th European Lupus Meeting
BOSTON, Mass., March 4, 2026 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric...
Read more
HotSpot Therapeutics to Present Preclinical Data from Small Molecule IRF5 Inhibitor Program at 15th European Lupus Meeting
BOSTON, Mass., February 26, 2026 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric...
Read more
HotSpot Therapeutics Presents Preclinical Data from Small Molecule CBM Signalosome Inhibitor Program at ESMO Gastrointestinal Cancers Congress 2025
BOSTON, Mass., July 4, 2025 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...
Read more
HotSpot Therapeutics to Present Preclinical Data from Small Molecule CBM Signalosome Inhibitor Program at ESMO Gastrointestinal Cancers Congress 2025
BOSTON, Mass., June 26, 2025 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...
Read more
HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Program at FOCIS 2025
BOSTON, Mass., June 25, 2025 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...
Read more
HotSpot Therapeutics to Present Preclinical Data from Small Molecule IRF5 Program at FOCIS 2025
BOSTON, Mass., June 18, 2025 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...
Read more
HotSpot Therapeutics Presents Additional Phase 1 Biomarker Data on Novel CBL-B Inhibitor HST-1011 at 2024 Society for Immunotherapy of Cancer Annual Meeting
BOSTON, Mass., November 7, 2024 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...
Read more
HotSpot Therapeutics Presents Preclinical Data from MALT1 CBM Signalosome Glue Program at 36th EORTC-NCI-AACR Symposium
BOSTON, Mass., October 23, 2024 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...
Read more
HotSpot Therapeutics to Present Preclinical Data from MALT1 CBM Signalosome Glue Program at 36th EORTC-NCI-AACR Symposium
BOSTON, Mass., October 9, 2024 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...
Read more
HotSpot Therapeutics to Present Additional Phase 1 Biomarker Data on Novel CBL-B Inhibitor HST-1011 at 2024 Society for Immunotherapy of Cancer Annual Meeting
BOSTON, Mass., October 4, 2024 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...
Read more
HotSpot Therapeutics Appoints Alison O’Neill, M.D., as Chief Medical Officer
BOSTON, Mass., September 19, 2024 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...
Read more
HotSpot Therapeutics Presents First-in-Human Phase 1 Clinical Data on its Novel CBL-B Inhibitor, HST-1011, at ESMO Congress 2024
BOSTON, Mass., September 12, 2024 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...
Read more
HotSpot Therapeutics to Present Initial First-in-Human Phase 1 Clinical Data on its Novel CBL-B Inhibitor, HST-1011, at ESMO Congress 2024
BOSTON, Mass., July 17, 2024 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...
Read more
HotSpot Therapeutics Presents Preclinical Data for Potential First-in-Class MALT1 Scaffolding Inhibitor at the 4th AACR International Meeting: Advances in Malignant Lymphoma
BOSTON, Mass., Jun. 20, 2024 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...
Read more
HotSpot Therapeutics to Present Additional Preclinical Data on Potential First-in-Class MALT1 Scaffolding Inhibitor at the 4th AACR International Meeting: Advances in Malignant Lymphoma
BOSTON, Mass., May 20, 2024 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...
Read more
HotSpot Therapeutics Presents Preclinical Data for Potential First-in-Class MALT1 Scaffolding Inhibitor at 65th ASH Annual Meeting
BOSTON, Mass., Dec. 11, 2023 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...
Read more
HotSpot Therapeutics Presents Preclinical Data from CBL-B Program at 2023 Society for Immunotherapy of Cancer Annual Meeting
BOSTON, Mass., Nov. 3, 2023 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...
Read more
HotSpot Therapeutics to Introduce First-in-Class MALT1 Scaffolding Inhibitor at 65th ASH Annual Meeting
BOSTON, Mass., Nov. 2, 2023 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...
Read more
HotSpot Therapeutics to Present Preclinical Data from CBL-B Program at 2023 Society for Immunotherapy of Cancer Annual Meeting
BOSTON, Mass., Sep. 27, 2023 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...
Read more
HotSpot Therapeutics Presents Preclinical Data from CBL-B Program at AACR Annual Meeting 2023
Preclinical data highlighted ability of HotSpot’s CBL-B inhibitors to enhance the effector function and proliferation of natural killer cells, which...
Read more
HotSpot Therapeutics Achieves First-In-Human Dosing with HST-1011, An Investigational Oral Small Molecule Allosteric Inhibitor of CBL-B
Phase 1/2 study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical activity of HST-1011 dosed as...
Read more
HotSpot Therapeutics to Present Two Poster Presentations on CBL-B Program at AACR Annual Meeting 2023
BOSTON, Mass., Mar. 14, 2023 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...
Read more
HotSpot Therapeutics Announces FDA Clearance of IND Application for HST-1011, An Investigational Small Molecule Allosteric Inhibitor of CBL-B
BOSTON, Mass., January 03, 2023 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...
Read more
AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline
NORTH CHICAGO, Ill. and BOSTON, Mass., December 06, 2022 – AbbVie (NYSE: ABBV) and HotSpot Therapeutics, Inc., a biotechnology company...
Read more
HotSpot Therapeutics Presents Preclinical Data from CBL-B Program at 2022 Society for Immunotherapy of Cancer Annual Meeting
BOSTON, Mass., November 10, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of orally delivered,...
Read more
HotSpot Therapeutics to Present Preclinical Data from CBL-B Program at 2022 Society for Immunotherapy of Cancer Annual Meeting
BOSTON, Mass., October 5, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small...
Read more
HotSpot Therapeutics Appoints Paul Thibodeau, Ph.D., as Chief Business Officer
BOSTON, Mass., July 25, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule...
Read more
HotSpot Therapeutics Appoints Jose Carmona to Board of Directors
BOSTON, Mass., July 19, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule...
Read more
HotSpot Therapeutics Presents Pre-Clinical Data on CBL-B Program at American Association for Cancer Research Annual Meeting 2022
BOSTON, Mass., Apr. 8, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first- and...
Read more
HotSpot Therapeutics to Present Pre-Clinical Data on CBL-B Program at American Association for Cancer Research Annual Meeting 2022
BOSTON, Mass., Mar. 8, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first- and...
Read more
HotSpot Therapeutics to Present at the BMO Biopharma Spotlight Series
BOSTON, Mass., Feb. 17, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first- and...
Read more
HotSpot Therapeutics and Caris Life Sciences Announce Collaboration to Advance Precision Medicine Development for Difficult-to-Drug Therapeutic Targets
BOSTON, Mass., Jan. 10, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first- and...
Read more
HotSpot Therapeutics Closes $100M Series C to Advance First-in-Class Allosteric Drug Discovery Platform to the Clinic
Boston, Mass., Nov 29, 2021 — HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-class allosteric...
Read more
HotSpot Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference
Boston, Mass., Nov. 16, 2021 — HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-class allosteric therapies...
Read more
HotSpot Therapeutics to Present New Data Indicating Successful Targeting of CBL-B at 2021 Society for Immunotherapy of Cancer Annual Meeting
Boston, Mass., Nov. 9, 2021 — HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-class allosteric...
Read more
HotSpot Therapeutics to Present at the Solebury Trout/BMO Fall Private Company Showcase
BOSTON, Mass. (Oct. 11, 2021) – HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery and development of first-in-class allosteric...
Read more
HotSpot Therapeutics Appoints Timothy Reilly as Chief Development Officer
BOSTON, Mass. (April 14, 2021) – HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery and development of first-in-class allosteric...
Read more
HotSpot Therapeutics Appoints Eva Jack as Chief Operating Officer
BOSTON, Mass. (November 17, 2020) – HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery and development of first-in-class allosteric...
Read more
HotSpot Therapeutics Completes $65 Million Series B Financing to Advance Pipeline of Novel Allosteric Medicines
BOSTON, Mass. (May 21, 2020) – HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery and development of first-in-class allosteric...
Read more
HotSpot Therapeutics Announces Acquisition of Macroceutics, Inc.
BOSTON, Mass. (August 23, 2019)— HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery of nature’s regulatory sites to advance...
Read more
HotSpot Therapeutics Expands Board of Directors and Management Team
CAMBRIDGE, Mass. (October 30th, 2018) – HotSpot Therapeutics, a biotechnology company pioneering the discovery of nature’s regulatory sites to advance...
Read more
HotSpot Therapeutics Completes $45 Million Series A Financing to Advance New Approach to Allosteric Drug Discovery
“HotSpot is targeting natural regulatory sites on proteins that evolution has perfected over many millions of years. This allows us...
Read more
In the News
AbbVie offers up to $335M for connection with HotSpot’s preclinical small-molecule program
AbbVie has formed a connection with HotSpot Therapeutics, inking a global licensing option deal for the biotech’s preclinical small-molecule allosteric therapy and extending the opportunity for up to $295 million in biobucks.
Read more
AbbVie puts up $40M to license a treatment from HotSpot Therapeutics
HotSpot Therapeutics has managed to gain some steam financially in the past few years, as the company wrangled several multi-million dollar raises. But its latest deal not only puts more cash into its pockets, it also connects with a major name in pharma.
Read more
HotSpot Therapeutics secures $100M to advance allosteric platform
Boston Neighbors Net $256 Million for Treg and Allosteric Therapies
HotSpot Therapeutics snags $100M series C to bring allosteric meds into the clinic
Cancer-Targeting Biotech Startup HotSpot Therapeutics Raises $100M
Atlas-backed startup raises $100M for protein ‘hotspots’
HotSpot gets hotter with $100M raise to push toward clinic
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
SR One fuels HotSpot’s $65M B round to fund allosteric R&D
Hotspot’s $65M series B to propel it into the clinic
Boston’s HotSpot Therapeutics Eyes The Clinic Following $65 Million Series B
HotSpot heads for clinic with $65M series B round to develop allosteric modulators
HotSpot announces $65M Series B, as Nimbus pioneers look to keep up in a crowding field
In the decade since Nimbus Therapeutics built a company around computation and little-known phenomena allosteric regulation, the industry has brimmed with algorithm companies and even a few chasing those same targets. Still, a couple of the old leaders think they can keep an edge.
Getting higher-quality hits out of DNA-encoded libraries
DNA-encoded libraries are quickly surpassing traditional high throughput screens as industry’s first stop for hit generation. Now, developers are taking the technology up a notch to get more tractable hits in the output.
HotSpot acquires DNA-encoded library firm Macroceutics
HotSpot Therapeutics, a biotech firm that launched last year to develop allosteric inhibitors for autoimmune and metabolic diseases, has acquired Macroceutics, a 5-year-old provider of DNA-encoded library screening technologies.
HotSpot Acquires Macroceutics for focused allosteric library
HotSpot is adding a key piece to its allosteric inhibitor platform through the acquisition of DNA-encoded library company Macroceutics: the technology to make chemical libraries tailored to allosteric, rather than active, sites.
Moving beyond the active site: why allostery is newly in fashion
Allosteric pockets on proteins have long been viewed as promising alternatives to active sites for controlling protein function. The problem has been finding them.
Drug hunters explore allostery’s advantages
After decades of focus on proteins’ active sites, a new crop of biotech firms is shifting attention to proteins’ hidden regulatory pockets
HotSpot debuts with $45m to find, drug natural allosteric sites
HotSpot Therapeutics Inc. (Cambridge, Mass.) emerged from stealth on Tuesday with a $45 million series A round co-led by Atlas Venture and Sofinnova Partners. T
HotSpot Therapeutics debuts with $45 million to pursue allosteric inhibitors
HotSpot Therapeutics is debuting with $45 million from Atlas Venture and Sofinnova Partners to explore allosteric inhibitors against tough-to-drug targets.
With $45M, HotSpot Takes Drug Research to New Biological Real Estate
In real estate, location is key. The same holds true in the hunt for new drugs. HotSpot Therapeutics is trying to break new ground in drug discovery by hitting locations on a protein that aren’t the conventional targets of most medicines.
Atlas, Sofinnova Bet $45M on ‘HotSpots’
Atlas Venture and Sofinnova Partners co-lead investment in a couple of Nimbus alumni
Hotspot Therapeutics Turns Up The Heat On Natural Allostery
HotSpot is pioneering a new approach to drugging the allosteric sites that Nature itself uses to control proteins.
Float like a butterfly: agility in biotech
In the quest towards building high-performing teams, biopharma can lift a page from the tech playbook around agile organizations.
Allostery: Realizing The Promise
With the discovery of the first allosteric inhibitors for bcr-abl that could offer the first clinical cures for CML, allosteric drug discovery is undergoing a resurgence.
Connect with us
HotSpot Therapeutics, Inc.
One Design Center Place
Suite 19-600
Boston, MA 02210